🚀 VC round data is live in beta, check it out!
Kymera Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Kymera Therapeutics and similar public comparables like Alkem Laboratories, Ono Pharmaceutical, Grifols, Merus and more.
Kymera Therapeutics Overview
About Kymera Therapeutics
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients’ lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
Founded
2015
HQ
Employees
188
Website
Sectors
Financials (LTM)
EV
$6B
Kymera Therapeutics Financials
Kymera Therapeutics reported last 12-month revenue of $39M and negative EBITDA of ($340M).
In the same LTM period, Kymera Therapeutics generated $39M in gross profit, ($340M) in EBITDA losses, and had net loss of ($322M).
Revenue (LTM)
Kymera Therapeutics P&L
In the most recent fiscal year, Kymera Therapeutics reported revenue of $39M and EBITDA of ($303M).
Kymera Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $39M | XXX | $39M | XXX | XXX | XXX |
| Gross Profit | $39M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($340M) | XXX | ($303M) | XXX | XXX | XXX |
| EBITDA Margin | (865%) | XXX | (772%) | XXX | XXX | XXX |
| EBIT Margin | (919%) | XXX | (881%) | XXX | XXX | XXX |
| Net Profit | ($322M) | XXX | ($311M) | XXX | XXX | XXX |
| Net Margin | (819%) | XXX | (794%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Kymera Therapeutics Stock Performance
Kymera Therapeutics has current market cap of $7B, and enterprise value of $6B.
Market Cap Evolution
Kymera Therapeutics' stock price is $87.66.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6B | $7B | 1.8% | XXX | XXX | XXX | $-3.81 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialKymera Therapeutics Valuation Multiples
Kymera Therapeutics trades at 162.5x EV/Revenue multiple, and (18.8x) EV/EBITDA.
EV / Revenue (LTM)
Kymera Therapeutics Financial Valuation Multiples
As of April 18, 2026, Kymera Therapeutics has market cap of $7B and EV of $6B.
Equity research analysts estimate Kymera Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kymera Therapeutics has a P/E ratio of (22.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7B | XXX | $7B | XXX | XXX | XXX |
| EV (current) | $6B | XXX | $6B | XXX | XXX | XXX |
| EV/Revenue | 162.5x | XXX | 163.0x | XXX | XXX | XXX |
| EV/EBITDA | (18.8x) | XXX | (21.1x) | XXX | XXX | XXX |
| EV/EBIT | (17.7x) | XXX | (18.5x) | XXX | XXX | XXX |
| EV/Gross Profit | 162.5x | XXX | — | XXX | XXX | XXX |
| P/E | (22.2x) | XXX | (23.0x) | XXX | XXX | XXX |
| EV/FCF | (21.7x) | XXX | (27.3x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Kymera Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Kymera Therapeutics Margins & Growth Rates
Kymera Therapeutics' revenue in the last 12 month grew by 3%.
Kymera Therapeutics' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $2.0M for the same period.
Kymera Therapeutics' rule of 40 is (927%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kymera Therapeutics' rule of X is (925%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Kymera Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | 1% | XXX | XXX | XXX |
| EBITDA Margin | (865%) | XXX | (772%) | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | 21% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (927%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (925%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $2.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 176% | XXX | 174% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 836% | XXX | 808% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 981% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Kymera Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Kymera Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Alkem Laboratories | XXX | XXX | XXX | XXX | XXX | XXX |
| Ono Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Grifols | XXX | XXX | XXX | XXX | XXX | XXX |
| Merus | XXX | XXX | XXX | XXX | XXX | XXX |
| Wantai BioPharm | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kymera Therapeutics M&A Activity
Kymera Therapeutics acquired XXX companies to date.
Last acquisition by Kymera Therapeutics was on XXXXXXXX, XXXXX. Kymera Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Kymera Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialKymera Therapeutics Investment Activity
Kymera Therapeutics invested in XXX companies to date.
Kymera Therapeutics made its latest investment on XXXXXXXX, XXXXX. Kymera Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Kymera Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Kymera Therapeutics
| When was Kymera Therapeutics founded? | Kymera Therapeutics was founded in 2015. |
| Where is Kymera Therapeutics headquartered? | Kymera Therapeutics is headquartered in United States. |
| How many employees does Kymera Therapeutics have? | As of today, Kymera Therapeutics has over 188 employees. |
| Who is the CEO of Kymera Therapeutics? | Kymera Therapeutics' CEO is Nello Mainolfi. |
| Is Kymera Therapeutics publicly listed? | Yes, Kymera Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Kymera Therapeutics? | Kymera Therapeutics trades under KYMR ticker. |
| When did Kymera Therapeutics go public? | Kymera Therapeutics went public in 2020. |
| Who are competitors of Kymera Therapeutics? | Kymera Therapeutics main competitors are Alkem Laboratories, Ono Pharmaceutical, Grifols, Merus. |
| What is the current market cap of Kymera Therapeutics? | Kymera Therapeutics' current market cap is $7B. |
| What is the current revenue of Kymera Therapeutics? | Kymera Therapeutics' last 12 months revenue is $39M. |
| What is the current revenue growth of Kymera Therapeutics? | Kymera Therapeutics revenue growth (NTM/LTM) is 3%. |
| What is the current EV/Revenue multiple of Kymera Therapeutics? | Current revenue multiple of Kymera Therapeutics is 162.5x. |
| Is Kymera Therapeutics profitable? | No, Kymera Therapeutics is not profitable. |
| What is the current EBITDA of Kymera Therapeutics? | Kymera Therapeutics has negative EBITDA and is not profitable. |
| What is Kymera Therapeutics' EBITDA margin? | Kymera Therapeutics' last 12 months EBITDA margin is (865%). |
| What is the current EV/EBITDA multiple of Kymera Therapeutics? | Current EBITDA multiple of Kymera Therapeutics is (18.8x). |
| What is the current FCF of Kymera Therapeutics? | Kymera Therapeutics' last 12 months FCF is ($294M). |
| What is Kymera Therapeutics' FCF margin? | Kymera Therapeutics' last 12 months FCF margin is (749%). |
| What is the current EV/FCF multiple of Kymera Therapeutics? | Current FCF multiple of Kymera Therapeutics is (21.7x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.